Cialis (Tadalafil) in Children Under 12: Transition to Adult Care

Why Tadalafil Appears in Pediatric Medicine at All

Tadalafil (brand names Adcirca, Alyq, and Cialis) is a phosphodiesterase type-5 (PDE5) inhibitor. Most adults recognize it as a treatment for erectile dysfunction. In children under 12, the drug serves a completely different purpose.

The Primary Pediatric Indication: Pulmonary Arterial Hypertension

PAH is a progressive disease of the pulmonary vasculature. PDE5 inhibitors reduce pulmonary vascular resistance by increasing cyclic GMP in smooth muscle cells of pulmonary arteries. That mechanism is valuable regardless of patient age.

The FDA approved tadalafil (Adcirca 40 mg once daily) for PAH in adults in 2009, based on the PHIRST trial (N=405), which showed a placebo-corrected improvement in 6MWD of 33 meters at 16 weeks (P<0.001) [1]. Pediatric use came later and remains largely off-label, guided by the TEMPO trial and smaller pharmacokinetic studies.

What TEMPO Showed

The TEMPO study (NCT01109966) enrolled children aged 2 to 17 with PAH and assessed tadalafil pharmacokinetics, safety, and exploratory efficacy at doses of approximately 1 mg/kg/day. Exposure-matched modeling suggested that 1 mg/kg/day achieved adult-equivalent plasma concentrations in most children above 20 kg body weight [2]. No serious unexpected safety signals were identified beyond those already known in adults, including headache, flushing, and myalgia.

Children below 20 kg showed higher weight-normalized clearance, meaning dose adjustments may be needed in the youngest or smallest patients.

Other Rare Pediatric Uses

Outside of PAH, tadalafil has been studied in small series for congenital heart defects involving elevated pulmonary pressure after surgical repair. These uses are strictly off-label and should be managed by a pediatric cardiologist or pulmonologist with experience in pulmonary hypertension. Sexual health indications, the context most adults associate with Cialis, have no established role or evidence base in children under 12 [3].

FDA Approval Status for Pediatric Patients

The FDA has not approved any PDE5 inhibitor specifically for sexual dysfunction in children under 12. Full stop. Any such use would be outside the bounds of current evidence and regulatory guidance.

What the Label Actually Says

The Adcirca prescribing information states the drug is indicated for adults with PAH to improve exercise ability. Pediatric dosing appears in the label only as a reference to ongoing studies and weight-based extrapolation, not as a confirmed approved indication for children [4].

The Cialis (tadalafil 2.5 to 20 mg) label for erectile dysfunction explicitly limits adult male use and contains no pediatric dosing information, because ED is not a condition addressed in pre-pubertal children [4].

Off-Label Prescribing Framework for PAH

When a pediatric cardiologist prescribes tadalafil off-label for PAH in a child under 12, the decision follows:

• Weight-based dosing from TEMPO and pharmacokinetic modeling (approximately 1 mg/kg/day)
• Institutional protocols at specialized pulmonary hypertension centers
• Guidance from the Pediatric Pulmonary Hypertension Network (PPHNet)
• Shared decision-making documentation with families

The American Heart Association and American Thoracic Society 2015 PAH guidelines note that PDE5 inhibitors "are reasonable to use in pediatric PAH patients based on adult data and limited pediatric pharmacokinetic studies," classifying the recommendation as Class IIa, Level of Evidence C [5].

Monitoring Requirements During Childhood

Children on long-term tadalafil for PAH require systematic monitoring. The monitoring burden shapes what the transition plan must hand off to adult providers.

Cardiovascular and Functional Monitoring

The standard monitoring schedule for stable pediatric PAH patients on tadalafil includes:

• Echocardiography every 3 to 6 months to assess right ventricular function and pulmonary pressures
• 6-minute walk distance (6MWD) testing every 3 to 6 months in children old enough to perform the test reliably (generally age 6 and above)
• Brain natriuretic peptide (BNP) or NT-proBNP at each visit as a hemodynamic surrogate
• Oxygen saturation monitoring at rest and with exertion

Children under 6 cannot reliably perform 6MWD testing, so functional class assessment and parental-reported activity tolerance substitute.

Laboratory and Drug Safety Monitoring

Tadalafil does not require routine liver function testing in otherwise healthy patients, but children with congenital liver abnormalities or those on hepatically metabolized co-medications need closer surveillance. CYP3A4 inhibitors (azole antifungals, clarithromycin, ritonavir) can raise tadalafil plasma levels significantly, a concern that grows as pediatric patients age and encounter broader medication exposures [6].

Growth and Development Considerations

Long-term PDE5 inhibitor use during childhood has not been associated with impaired growth or pubertal development in published series, but the dataset is small. Clinicians should document Tanner staging at each annual visit to identify any unexpected developmental signals.

Planning the Transition to Adult Care

Transition from pediatric to adult care is among the highest-risk periods for any patient with a chronic condition. Studies across multiple chronic diseases show that transfer to adult care without a structured program is associated with 30 to 50% rates of treatment interruption in the first two years [7]. For a child with PAH on tadalafil, even a brief interruption can precipitate clinical deterioration.

When to Start Transition Planning

Most pediatric pulmonary hypertension centers begin formal transition discussions at age 14, with active transfer occurring between 18 and 21 depending on the patient's cognitive readiness and local adult program capacity. The American College of Cardiology and American Heart Association recommend beginning transition planning "no later than 12 years of age for patients with congenital heart disease," a principle extended by many centers to all pediatric cardiovascular conditions [8].

Starting at 14 gives four years to:

1. Educate the patient directly about their diagnosis, medication name, dose, and purpose
2. Build self-management skills (filling prescriptions, recognizing side effects)
3. Identify an adult PAH specialist willing to accept transfer
4. Conduct at least one overlap visit with both pediatric and adult providers present

The Transfer Package

When the formal handoff occurs, the receiving adult provider needs a complete clinical summary. A well-constructed transfer package for a tadalafil-treated PAH patient should include:

• Complete diagnosis history, including catheterization data confirming PAH classification (Group 1 vs. Secondary)
• Full medication list with current tadalafil dose in mg/kg and absolute mg
• Last echocardiography report and trend data from prior 2 years
• 6MWD trend data
• BNP or NT-proBNP trend
• Prior hospitalization records for PAH decompensation
• Documented drug allergy and drug interaction history
• Insurance and pharmacy information

The HealthRX Pediatric-to-Adult Tadalafil Transition Checklist (see framework insert) formalizes these elements into a one-page handoff document that pediatric teams can complete at the final pre-transfer visit.

The Adult Provider's Role at Intake

Adult PAH specialists receiving a transferred patient should not assume the pediatric dose is optimal for the now-larger patient. Body weight changes during adolescence may mean a patient who was appropriately dosed at 20 mg/day at age 14 is now significantly underdosed at 18. The adult provider should recalculate based on current weight and consider whether full adult dosing (40 mg once daily for PAH) is now appropriate [9].

Renal function should also be reassessed. The Adcirca label contraindicates use in patients with severe renal impairment (creatinine clearance <30 mL/min), and this calculation changes as body composition matures [4].

Drug Interactions That Become More Relevant at Transition

As patients age from childhood into adolescence and young adulthood, the risk profile for drug interactions with tadalafil expands. Clinicians at the transition point should address these proactively.

Nitrates: The Absolute Contraindication

Nitrates and tadalafil together produce severe hypotension. This contraindication does not change with age. The adult provider must document this clearly in the chart and ensure the patient understands it before any dental or cardiac procedure involving nitroglycerin.

Alcohol and Recreational Substances

Young adults are more likely than children to consume alcohol. Alcohol combined with tadalafil can lower blood pressure additively. The FDA label notes that when tadalafil 20 mg was co-administered with alcohol in healthy volunteers, mean maximum decreases in systolic blood pressure reached 7 mmHg compared to alcohol alone [4]. Patients transitioning to adult care need explicit counseling on this point.

Alpha-Blockers

Patients who develop hypertension in young adulthood may be prescribed alpha-blockers. Co-administration with tadalafil requires careful blood pressure monitoring, as symptomatic hypotension has been reported with the combination [4].

Hormonal Therapies

Adolescent patients, particularly females, may begin hormonal contraception around the time of transition. Estrogen-containing oral contraceptives do not have a pharmacokinetic interaction with tadalafil, but the underlying pulmonary hypertension diagnosis means hormonal contraception choices are complex and should involve the PAH team. The Endocrine Society and AHA both advise against estrogen-containing contraceptives in patients with WHO Functional Class III to IV PAH due to thromboembolism risk [10].

Safety Profile Considerations Specific to the Under-12 Age Group

Adverse Effects Observed in Pediatric Trials

In the TEMPO pharmacokinetic study, adverse effects in pediatric patients mirrored the adult safety profile. Headache was the most commonly reported adverse effect. Flushing and nasopharyngitis were also reported. No cases of non-arteritic anterior ischemic optic neuropathy (NAION) were reported in the pediatric dataset, though this rare adverse effect is listed on the adult label with a warning [2].

Hypotension, a theoretically amplified concern in small children, was not reported as a serious adverse event in TEMPO at doses of approximately 1 mg/kg/day. This aligns with the drug's selectivity for pulmonary vasculature over systemic vessels at therapeutic doses in PAH.

Sudden Hearing Loss

The FDA added a warning for sudden hearing loss to tadalafil labeling in 2007 after post-marketing reports. The mechanism remains unclear. Pediatric cases are not well-documented in the literature, but the warning carries through to pediatric use by default [4]. Audiometric baseline and monitoring has not been formally recommended in guidelines, but clinicians with pediatric patients reporting acute hearing changes should consider this potential adverse effect.

Erections in Pre-Pubertal Males: A Clinical Reality

Pre-pubertal boys prescribed tadalafil for PAH may experience erections as a side effect, as the drug's vasodilatory mechanism is not limited by pubertal status. This is physiologically expected and not harmful, but it requires age-appropriate discussion with families at the time of prescription. As the patient ages through puberty, this side effect warrants direct, non-stigmatizing conversation with the patient.

Practical Guidance for Families Navigating This Transition

Parents who have managed a child's tadalafil prescription for years often feel significant anxiety about handing that responsibility to a new adult-medicine team. The following steps reduce that anxiety with concrete actions.

Building the Patient's Own Knowledge Base

By age 16, a patient on tadalafil for PAH should be able to state:

• The name of the drug and why they take it
• The current dose in milligrams
• The name of the condition being treated
• What side effects to report and to whom
• That nitrates are absolutely contraindicated with their medication

Pediatric teams can assess this knowledge annually using a simple verbal check-in. Research on congenital heart disease transitions shows that patients who demonstrate self-knowledge by age 16 are significantly less likely to have treatment gaps after transfer [11].

Insurance Continuity

Tadalafil for PAH (Adcirca or Alyq) is not inexpensive. Monthly costs without insurance can exceed $2,000. Transition planning must include a review of insurance coverage changes that occur at age 18 or 26 under the Affordable Care Act. Social work involvement at the pediatric center, beginning at age 16, helps families anticipate these transitions before they cause a prescription gap.

Pharmacy Consistency

Patients who have filled the same prescription at the same pharmacy for years benefit from continuity at that pharmacy through the transition. The adult provider should attempt to send the first adult prescription to the same pharmacy the family already uses, reducing friction at a high-risk handoff moment.

What Adult Providers Should Know When Receiving a Transfer Patient

Adult internists, cardiologists, and pulmonologists who did not train in pediatric PAH may be unfamiliar with the weight-based dosing history these patients bring with them. Three points deserve emphasis.

First, the patient's tadalafil prescription may be written as Adcirca, not Cialis. These are the same molecule at different approved doses and formulations. Adcirca 40 mg once daily is the PAH dose. Cialis 5 to 20 mg is the ED or BPH dose. Prescribing the wrong formulation creates both therapeutic and insurance problems.

Second, the 40 mg once-daily PAH dose is higher than most adult ED doses. An adult provider unfamiliar with PAH management may inadvertently reduce the dose thinking it is excessive, compromising pulmonary hemodynamics.

Third, the underlying PAH diagnosis requires its own ongoing management beyond the tadalafil prescription. Tadalafil monotherapy may have been appropriate at pediatric doses, but adult PAH guidelines from the European Society of Cardiology recommend combination oral therapy (typically a PDE5 inhibitor plus an endothelin receptor antagonist) in most treatment-naive adults with PAH [12]. The adult provider should assess whether combination therapy is warranted at the time of transfer.